| Literature DB >> 25939958 |
Cristina Garrido Colmenero1, Gonzalo Blasco Morente1, Jesús Tercedor Sánchez1.
Abstract
Cyclosporine A (CyA) is a systemic therapy used to control severe atopic dermatitis (AD) in children, but its use may be associated with serious side effects. Intermittent short-course therapy has been used to minimize these risks without the loss of clinical benefits. We conducted a 20-week study using intermittent short-course CyA therapy in five patients with severe AD and a Scoring Atopic Dermatitis (SCORAD) score >40. The result was a reduction in the cumulative dose of CyA and serum CyA level, which allows for a longer duration of CyA treatment and decreases the risk of relapse in patients with severe AD.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25939958 DOI: 10.1111/pde.12592
Source DB: PubMed Journal: Pediatr Dermatol ISSN: 0736-8046 Impact factor: 1.588